Document is current
Any future updates will be listed below
-
Authors
Moreno, F.
Iranzo, V. https://orcid.org/0000-0001-6183-5173
Álvarez, I.
Antón, A.
Chacón, J. I.
Gavilá, J.
Martín, M.
Sánchez Rovira, P.
Gratal, P.
Fernández González, M. J.
López, R.
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 26 December 2024
Accepted: 27 February 2025
First Online: 27 March 2025
Declarations
:
: FM has received research funding from Pfizer; consulting/advisory fees from Pfizer, Novartis, AstraZeneca, MSD, Daiichi-Sankyo, Seagen, and Pierre Fabre; travel expenses from Pfizer, Novartis, and Gilead; and speaker fees from Pfizer and Novartis. VI has received consulting/advisory fees from Genomic Health, Roche, Pfizer, Advanced Accelerator Applications, AstraZeneca, and MSD; and speaker fees from Ipsen, Roche, Novartis, Pfizer, Eisai, Daiichi-Sankyo, AstraZeneca, Pierre Fabre, Teva, Seagen, Eli Lilly, and Gilead. IA has received research funding from AstraZeneca, Pfizer, Novartis, Roche; consulting/advisory fees from AstraZeneca, Pfizer, Roche, Palex, Seagen, Gilead, MSD, Novartis; travel expenses from AstraZeneca, Pfizer, Roche, Eisai, Eli Lilly, Daiichi-Sankyo, MSD; and speaker fees from AstraZeneca, Pfizer, Novartis, Roche, Eisai, MSD. AA has received honoraria for participation in advisory boards from Seagen and Daiichi-Sankyo; and speaker fees from Eli Lilly, Pfizer, Novartis, Roche, and Daiichi-Sankyo. JG has received funding from Novartis, Eli Lilly, Pfizer, Daiichi-Sankyo, and AstraZeneca. MM has received research funding from Roche, PUMA and Novartis; consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo and Pfizer; and speaker fees from AstraZeneca, Eli Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer. RL has received research funding from Roche and Merck; honoraria for participation in advisory boards from Roche, AstraZeneca, Merck, MSD, Bayer, BMS, Novartis, Janssen, Eli Lilly, Pfizer and Leo; travel expenses from Pharmamar, Roche, BMS and Pierre Fabre; and is co-founder and shareholder in Nasasbiotech, Diversa Technologies. JIC, PSR, PG, and MJFG have no conflicts of interest.
: This study did not involve humans and did not require approval by an Ethical Committee.
: This study did not involve humans and informed consent was not necessary.
